Im­muno­Gen's lead armed an­ti­body fal­ters in key ovar­i­an can­cer test as a monother­a­py — shares crash

Im­muno­Gen’s lead armed an­ti­body — mirve­tux­imab so­rav­tan­sine — has failed a late-stage study as a monother­a­py in third line plat­inum-re­sis­tant ovar­i­an can­cer pa­tients, a miss that could de­rail stud­ies test­ing the drug as part of a com­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER